Dogwood Therapeutics, Inc.
DWTX
Rank in Stocks
#23799
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Share Price
$1.12
Last synced: 2026-11-12
Market Cap
$38.23M
Change (1 day)
-5.08%
Change (1 year)
-79.49%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Dogwood Therapeutics, Inc. (DWTX)
Category
Healthcare
EPS for Dogwood Therapeutics, Inc. (DWTX)
EPS as of September 2026 TTM: $-0.89
According to Dogwood Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.89. At the end of 2025 the company had an EPS of $-4.32, an increase over its 2024 EPS of $-12.52.
EPS history for Dogwood Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.89 | -79.40% |
| 2025 | $-4.32 | -65.50% |
| 2024 | $-12.52 | 77.59% |
| 2023 | $-7.05 | -74.51% |
| 2022 | $-27.66 | -42.25% |
| 2021 | $-47.90 | -8.76% |
| 2020 | $-52.50 | 310.16% |
| 2019 | $-12.80 | 17.11% |
| 2018 | $-10.93 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,859.55% |
US
|
|
| $-7.07 | 694.38% |
US
|
|
| $-5.29 | 494.38% |
AU
|
|
| $12.88 | -1,547.20% |
BE
|
|
| $21.56 | -2,522.47% |
NL
|
Questions about Dogwood Therapeutics, Inc.'s earnings per share (EPS)
What is Dogwood Therapeutics, Inc.'s earnings per share (EPS)?
Dogwood Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.89, as of Sep 2026.
What was Dogwood Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Dogwood Therapeutics, Inc.'s earnings per share (EPS) was $-4.32, compared with $-12.52 in 2024.
How has Dogwood Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Dogwood Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-4.32) and lowest in 2020 ($-52.50).
How does Dogwood Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Dogwood Therapeutics, Inc.'s earnings per share (EPS) ($-0.89) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.